Evidence map›Paper›PMID 34691041›Full record

ArticleFrontiers in immunology2021

Depletion of T cells

Alexandre Klopp, Sophia Schreiber, Anna D Kosinska, Martin Pulé, Ulrike Protzer, Karin Wisskirchen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Alexandre KloppSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.
Sophia SchreiberSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.
Anna D KosinskaSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.
Martin PuléDepartment of Haematology, Cancer Institute, University College London, London, United Kingdom.
Ulrike ProtzerSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.
Karin WisskirchenSchool of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.
German Center for Infection Research · DETechnical University of Munich · DEHelmholtz Zentrum München · DEUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell therapy with T cells that are re-directed to hepatitis B virus (HBV)-infected cells by virus-specific receptors is a promising therapeutic approach for treatment of chronic hepatitis B and HBV-associated cancer. Due to the high number of target cells, however, side effects such as cytokine release syndrome or hepatotoxicity may limit safety. A safeguard mechanism, which allows depletion of transferred T cells on demand, would thus be an interesting means to increase confidence in this approach. In this study, T cells were generated by retroviral transduction to express either an HBV-specific chimeric antigen receptor (S-CAR) or T-cell receptor (TCR), and in addition either inducible caspase 9 (iC9) or herpes simplex virus thymidine kinase (HSV-TK) as a safety switch. Real-time cytotoxicity assays using HBV-replicating hepatoma cells as targets revealed that activation of both safety switches stopped cytotoxicity of S-CAR- or TCR-transduced T cells within less than one hour.

Indexed as

Adoptive TransferAnimalsCaspase 9Cell DeathCell LineCoculture TechniquesCytokinesCytotoxicity, ImmunologicDisease Models, AnimalDNA-Binding ProteinsEnzyme InductionFemaleHepatitis B AntigensHepatitis B, ChronicHepatitis B virusHumansCASP9 protein, humanCaspase 9CytokinesDNA-Binding ProteinsHepatitis B AntigensIl2rg protein, mouseInterleukin Receptor Common gamma SubunitRag2 protein, mouseReceptors, Chimeric AntigenThymidine Kinasechimeric antigen receptor (CAR)chronic hepatitis Binducible caspase 9safeguard moleculessuicide switchT-cell therapy

Identifiers

PMID34691041
PMCPMC8527178
OpenAlexW3204162538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.